A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
Status:
Completed
Trial end date:
2020-06-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety,
tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with
metastatic castration-resistant prostate cancer (mCRPC).